Macquarie completes rare $1 billion risk transfer as private credit firms adopt bank tools

Macquarie Capital has completed a rare and sizeable risk transfer tied to roughly $1 billion of high-yield corporate loans, a deal that illustrates how large private credit platforms are adapting bank-style tools to manage credit exposure.

According to GuruFocus, the transaction, on which Alvarez & Marsal acted as adviser, was quietly completed by Macquarie’s corporate advisory and principal investment arm. Representatives for both Macquarie Capital and Alvarez & Marsal declined to comment, leaving public details limited. The move nonetheless signals that non-bank lenders are increasingly using synthetic risk-transfer (SRT) structures more commonly associated with banks to hedge concentrated exposures and manage capital cushions as private credit books grow.

Risk transfers have traditionally been a banking tool, used to insure slices of loan portfolios, often in the order of 5% to 15% of exposure, thereby supporting regulatory capital and solvency metrics. Although private credit lenders are not subject to Basel rules, industry participants and advisers evaluate whether their own capital buffers are adequate to absorb shocks; using SRTs allows them to reduce exposure to selected industries or borrowers without selling whole loans. Industry reports show a steady uptick in such transactions: Deutsche Bank increased a leveraged-loan SRT by $1 billion after strong investor demand in September 2024, and GoldenTree bought an SRT tied to about €1.2 billion of loans that same month, underscoring growing investor appetite for taking on tranche-specific credit risk.

The Macquarie transaction follows a period of strategic repositioning at the group. Bloomberg reported that in February 2025 Macquarie Group closed its U.S. debt capital markets business and shifted resources toward private credit, a move that affected roughly 80 staff and reflected a deliberate pivot into the asset class. Later coverage by Bloomberg in September 2025 noted Macquarie’s engagement of Alvarez & Marsal to explore a potential SRT, consistent with the adviser’s role on the completed deal.

Market participants expect the SRT market to expand further. Man Group has estimated the market could double in size over five years as banks in Europe and the U.S. deepen their use of these instruments. Private-credit firms and asset managers are also raising capital specifically to participate in SRT opportunities: Bloomberg reported that Manulife’s CQS raised $1.1 billion in November 2025 to invest in synthetic-risk transfers, while Morgan Stanley planned an SRT tied to a $6 billion private-loan portfolio with a potential $750 million tranche in October 2025.

Taken together, these developments suggest SRTs are migrating from a toolbox dominated by regulated banks into a broader ecosystem of alternative lenders and asset managers. For large private credit platforms such as Macquarie Capital, which reported a private credit portfolio equivalent to A$25.9 billion at the end of September, the use of SRTs offers a way to tailor risk retention, access investor capital willing to take first-loss or layered positions, and manage portfolio concentration without wholesale loan disposals.

The discreet nature of the Macquarie deal, and the refusal of involved parties to comment publicly, mean some details remain opaque, most notably the tranche size, pricing and identity of any risk-taking investors. Nevertheless, the transaction fits a clear market pattern: SRTs are becoming an increasingly accepted mechanism for distributing private-market credit risk between originators, banks and third-party investors, reshaping how both regulated and non‑regulated lenders think about capital and credit allocation.